eli lilly

  1. FDA tells Eli Lilly it can quickly refile NDA for hopeful Baricitinib

    Lilly will resubmit the New Drug Application for rheumatoid arthritis medication baricitinib, to the U.S. Food and Drug Administration (FDA), before the end of January 2018. The companies anticipate the FDA will classify the application as a Class II resubmission, which will start a new...

  2. Will this partnership help Lilly in the long run?

    Eli Lilly join hands with Nektar to co-develop NKTR-358, Because of the $400 million deal, Lilly has reduced its outlook.
    • Norman Foster
    • Thread
    • deal eli lilly nektar therapeautics partnership
    • Replies: 0
    • Forum: Eli Lilly
Top Bottom
Back